MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

Product Launch - MiMedx Group Inc announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed for complex wound management in surgical settings [1] - HELIOGEN contains Type I and Type III collagen, mimicking the native composition of structural connective tissue, and is shelf-stable [1] Strategic Expansion - The launch of HELIOGEN represents a strategic initiative to expand the company's surgical footprint, following the successful introduction of two new surgical products in late 2022 [2] - HELIOGEN is the company's first xenograft option and 510(k) cleared product, complementing its existing placental-based solutions in the surgical market [2] Product Features - HELIOGEN is a bovine-derived collagen matrix product indicated for managing moderately to heavily exudating wounds and controlling minor bleeding [3] - The product supports wound healing by allowing cell adhesion and migration into the wound site, and is provided in particulate form to conform to various wound types [3] Company Overview - MiMedx is a pioneer in wound care, with over a decade of experience in helping clinicians manage chronic and hard-to-heal wounds [4] - The company focuses on providing a leading portfolio of products for wound care, burn, and surgical sectors, aiming to be the global leader in healing solutions through innovation [4]